One of the largest pharmaceutical manufacturers in Russia, "PFC Obnovlenie" (Renewal), plans to complete construction of the first section of its large Workshop No. 7 by 2026 and move on to the licensing stage. This was reported to TASS by the company's executive director, Vladimir Grechkin.
“We are continuing to build the largest seventh workshop. Next year, we plan to prepare the first section for licensing. This will involve solid dosage forms,” the agency's interlocutor said.
The workshop will specialize in the production of solid dosage forms, including capsules, tablets, and effervescent tablets, according to the company’s press service. On the section scheduled for completion in 2026, the production of such drugs as acetylsalicylic acid, paracetamol, vitamin C, diclofenac, nimesulide, ibuprofen, bisoprolol, piracetam, indapamide, and others will be expanded. Previously, it was reported that after the launch of the workshop, the company’s capacity for this type of drug formulation will increase by 200 million packages per year.
The company is also continuing to develop its production site in the working settlement of Suzun, as noted in the press service of Renewal. "In particular, preparations are currently underway for the development of engineering batches of suppository formulations, qualification of equipment, and validation of technological processes," the organization explained.
Overall, the investment program, taking into account the construction of new workshops and modernization of production at Renewal, is estimated at 3.5 billion rubles, Grechkin informed the agency.
About the Company:
Renewal is one of the largest pharmaceutical manufacturers in Russia, holding between 2% and 85% of the domestic market depending on the pharmaceutical cluster. The production-research complex is located in Novosibirsk and the working settlement of Suzun. Since 1997, the company has been engaged in the development and production of medicinal products. The company’s drug portfolio includes various forms of medications, including analgesics, antiseptics, spasmolytics, cardiovascular drugs, antibiotics, injectable solutions, and ENT group medications.
According to the results of 2024, the pharmaceutical company increased the total volume of drug production to 206 million packages, with a growth of 21% compared to the previous year.
Source: @финансы
